

CITATION REPORT

List of articles citing

Switching between reference adalimumab and biosimilars in chronic immune-mediated inflammatory diseases: A systematic literature review

DOI: 10.1111/bcp.15101

British Journal of Clinical Pharmacology, 2021, , .

Source: <https://exaly.com/paper-pdf/91182751/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
9	Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. <i>BioDrugs</i> , 2021 , 35, 715-733	7.9	4
8	Secukinumab Loss of Efficacy Is Perfectly Counteracted by the Introduction of Combination Therapy (Rescue Therapy): Data from a Multicenter Real-Life Study in a Cohort of Italian Psoriatic Patients That Avoided Secukinumab Switching.. <i>Pharmaceuticals</i> , 2022 , 15,	5.2	2
7	Pharmacoeconomic rationale for switching patients with rheumatic diseases from original biologic disease-modifying antirheumatic drugs to biosimilars in context of the Russian healthcare system. <i>Sovremennaya Revmatologiya</i> , 2022 , 16, 1-17	0.7	0
6	Patient perspectives of successful adalimumab biosimilar transitioning in Crohn's disease: an interview study. <i>European Journal of Hospital Pharmacy</i> , ejhpharm-2022-003371	1.6	
5	Switching from reference adalimumab to biosimilar. Assessment of clinical outcomes in psoriasis.		
4	Documento de consenso sobre los medicamentos biosimilares en enfermedades inmunomediadas en Espa ^ñ . 2023 ,		0
3	Projected 2023 cost reduction from TNF-alpha inhibitor biosimilars in dermatology: a national Medicare analysis.		0
2	Actualizaci ³ n en el posicionamiento del Grupo Espa ^ñ ol de Psoriasis (GPS) en la utilizaci ³ n de medicamentos biosimilares en psoriasis moderada-grave. 2023 ,		0
1	A review article of inflammatory bowel disease treatment and pharmacogenomics. 2023 , 12,		0